UA80388C2 - Use of fulvestrant in the treatment of resistant breast cancer - Google Patents

Use of fulvestrant in the treatment of resistant breast cancer Download PDF

Info

Publication number
UA80388C2
UA80388C2 UA2002118734A UA2002118734A UA80388C2 UA 80388 C2 UA80388 C2 UA 80388C2 UA 2002118734 A UA2002118734 A UA 2002118734A UA 2002118734 A UA2002118734 A UA 2002118734A UA 80388 C2 UA80388 C2 UA 80388C2
Authority
UA
Ukraine
Prior art keywords
treatment
fulvestrant
disease
patients
breast cancer
Prior art date
Application number
UA2002118734A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA80388(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA80388C2 publication Critical patent/UA80388C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UA2002118734A 2000-04-05 2001-02-04 Use of fulvestrant in the treatment of resistant breast cancer UA80388C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (1)

Publication Number Publication Date
UA80388C2 true UA80388C2 (en) 2007-09-25

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002118734A UA80388C2 (en) 2000-04-05 2001-02-04 Use of fulvestrant in the treatment of resistant breast cancer

Country Status (28)

Country Link
US (2) US20030158166A1 (OSRAM)
EP (2) EP1586323A1 (OSRAM)
JP (1) JP2003528919A (OSRAM)
KR (1) KR100757764B1 (OSRAM)
CN (1) CN1431905A (OSRAM)
AT (1) ATE306270T1 (OSRAM)
AU (2) AU2001244372B2 (OSRAM)
BR (1) BR0109789A (OSRAM)
CA (1) CA2403608A1 (OSRAM)
CH (1) CH1272195H1 (OSRAM)
CZ (1) CZ303096B6 (OSRAM)
DE (1) DE60113975T2 (OSRAM)
DK (1) DK1272195T3 (OSRAM)
EE (1) EE05026B1 (OSRAM)
ES (1) ES2248300T3 (OSRAM)
GB (1) GB0008172D0 (OSRAM)
HU (1) HU230064B1 (OSRAM)
IL (2) IL151932A0 (OSRAM)
IS (1) IS2869B (OSRAM)
MX (1) MXPA02009744A (OSRAM)
NO (1) NO329949B1 (OSRAM)
NZ (1) NZ539603A (OSRAM)
PL (1) PL201175B1 (OSRAM)
RU (1) RU2265438C2 (OSRAM)
SK (1) SK287779B6 (OSRAM)
UA (1) UA80388C2 (OSRAM)
WO (1) WO2001074366A1 (OSRAM)
ZA (1) ZA200207538B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SG194735A1 (en) * 2011-05-09 2013-12-30 Univ Virginia Patent Found Compositions and methods for treating cancer
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
US20210253626A1 (en) * 2018-05-24 2021-08-19 Kashiv Biosciences, Llc Prodrugs of fulvestrant
KR20220042352A (ko) 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
EP4110344A4 (en) * 2020-02-29 2024-03-13 The University Of Vermont USE OF THYROMIMETICS TO TREAT CANCER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
BR0109789A (pt) 2003-01-21
PL201175B1 (pl) 2009-03-31
EP1272195B1 (en) 2005-10-12
NO20024735L (no) 2002-11-27
CA2403608A1 (en) 2001-10-11
US20110183949A1 (en) 2011-07-28
HUP0300339A3 (en) 2009-01-28
ATE306270T1 (de) 2005-10-15
DE60113975D1 (de) 2006-02-23
DK1272195T3 (da) 2006-01-16
GB0008172D0 (en) 2000-05-24
EE05026B1 (et) 2008-06-16
CN1431905A (zh) 2003-07-23
JP2003528919A (ja) 2003-09-30
HU230064B1 (hu) 2015-06-29
CZ303096B6 (cs) 2012-04-04
EP1272195A1 (en) 2003-01-08
IS6576A (is) 2002-10-01
IS2869B (is) 2014-03-15
NO20024735D0 (no) 2002-10-02
RU2265438C2 (ru) 2005-12-10
ES2248300T3 (es) 2006-03-16
ZA200207538B (en) 2003-12-19
IL151932A (en) 2007-07-04
WO2001074366A1 (en) 2001-10-11
PL357936A1 (en) 2004-08-09
MXPA02009744A (es) 2004-02-26
US20030158166A1 (en) 2003-08-21
KR20030007501A (ko) 2003-01-23
NZ539603A (en) 2008-02-29
CH1272195H1 (OSRAM) 2019-10-15
SK14292002A3 (sk) 2003-08-05
AU4437201A (en) 2001-10-15
AU2001244372B2 (en) 2006-02-16
DE60113975T2 (de) 2006-06-22
EE200200574A (et) 2004-04-15
HK1051498A1 (en) 2003-08-08
NO329949B1 (no) 2011-01-31
SK287779B6 (sk) 2011-09-05
IL151932A0 (en) 2003-04-10
KR100757764B1 (ko) 2007-09-12
CZ20023309A3 (cs) 2003-02-12
HUP0300339A2 (hu) 2003-06-28
EP1586323A1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
US10034860B2 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CN108135177B (zh) 用于治疗癌症的方法
Bloom et al. Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases
US12115146B2 (en) Treatment of skeletal-related events for breast cancer patients
ES3018358T3 (es) Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
Joffe et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report.
AT510868A2 (de) Fulvestrant in einer Dosierung von 500 mg für die Behandlung fortgeschrittenen Brustkrebses
US20220257552A1 (en) Methods of prescreening and treating breast cancers with selective androgen receptor modulators
Malisic et al. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia
EP4663633A1 (en) Combined pharmaceutical composition of substituted 2-hydrogen-pyrazole derivative and use thereof
Buzzoni et al. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group
JP2003523311A (ja) 乳癌の治療のためのｈＣＧ療法
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer
JP2025524365A (ja) 黄体形成ホルモン受容体作動薬を用いた肥満の治療方法
Kothari et al. The Treatment of Advanced Breast Cancer: Focus on Fulvestrant.
i Alsina et al. Selective Estrogen Receptor Modulators. Antonio Cano
i Alsina et al. SERMs and the Breast